We first analyzed the correlation between IC50 in response to Lenvatinib and BCL2L2 expression in the transfected LR-HCC cells and found that these cells became sensitive to Lenvatinib treatment after inhibition of BCL2L2 expression (Fig. 5d-e). This evidence concerns the gene BCL2L2 and hepatocellular carcinoma.